After six months of taking statins, over 20% of people develop muscle pain

This study was published in Arquivos Brasileiros de Cardiologia 2014 Jul;103(1):33-40

 

Study title and authors:

Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern brazilian cohort.

Smiderle L, Lima LO, Hutz MH, Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Almeida S, Fiegenbaum M.

Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.

 

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/25120083

This study evaluated the effects of simvastatin/atorvastatin on men and women. The six month study included 495 patients, aged 25-82 years, (331 women and 164 men), who received simvastatin/atorvastatin.

When high levels of creatine phosphokinase are detected in the blood, it is considered to be an abnormal result. High levels of the enzyme may occur due to the following conditions:

• heart attack
• pericarditis after a heart attack
• polymyositis or dermamyositis
• heart muscle inflammation
• myopathy (a disease of the muscles)
• rhabdomyolysis (a breakdown of muscle tissues)
• muscular dystrophies
• convulsions
• stroke
• brain injury
• delirium tremens
• hypothyroidism (a decrease in the activity of the thyroid gland) or hyperthyroidism (an increase in activity of the thyroid gland)
• death of lung tissue

After six months the study found:
(a) 20.3% of the patients developed muscle pain.
(b) 11.1% of the patients had increased creatine phosphokinase levels and/or abnormal liver function.

Statins increase the risk of serious adverse cardiovascular events

This study was published in the Journal of the American Medical Association 2007 Mar 28;297(12):1344-53

 

Study title and authors:

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.

Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group.

Department of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA. jrcrouse@wfubmc.edu

 

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/17384434

This study investigated the effects of statins in participants with a low risk of heart disease. The two year study was a randomised, double-blind, placebo-controlled trial of 984 individuals, average age 57 years. The participants received either a daily 40-mg dose of rosuvastatin or placebo.

The study found:
(a) Cholesterol levels reduced by 33% in the statin users and remained the same in those on placebo.
(b) Low density lipoprotein (LDL) cholesterol levels reduced by 49% in the statin users and remained the same in those on placebo.
(c) Statin users had a 21% increased risk of death compared to placebo.
(d) Statin users had a 423% increased risk of a serious adverse cardiovascular event compared to placebo.
(e) Statin users had a 4% increased risk of any adverse event compared to placebo.
(f) Statin users had a 5% increased risk of developing cancer compared to placebo.
(g) Statin users had a 5% increased risk of muscle pain compared to placebo.
(h) Statin users had a 121% increased risk of elevated liver enzymes compared to placebo.
(i) Statin users had a 56% increased risk of developing arthritis compared to placebo.



Statins, fibrates and beta blockers increase fatigue during moderate intensity exercise

This study was published in the British Journal of Clinical Pharmacology 1997 Mar;43(3):291-300

 

Study title and authors:

The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects.

Eagles CJ, Kendall MJ.

Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.

 

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/9088584

This study examined the effects of different combinations of beta blockers (metoprolol and atenolol) and cholesterol-lowering drugs (fluvastatin and bezafibrate), on fatigue during moderate intensity exercise in healthy young volunteers. The study included 14 healthy men and women, average age 21.9 years, who completed five, 90 minute walks after been treated with either four different combinations of metoprolol or atenolol and fluvastatin or bezafibrate, or placebo.

The study found:
(a) Fat oxidation was between 24% to 40 % lower in subjects treated with beta blockers and cholesterol lowering drugs compared to subjects on placebo. 
(b) Ammonia levels were between 51% to 170 % higher in subjects treated with beta blockers and cholesterol lowering drugs compared to subjects on placebo. (High ammonia levels can lead to lack of energy and brain damage).
(c) Scores on the feeling scale were significantly lower in subjects treated with beta blockers and cholesterol lowering drugs compared to subjects on placebo. (i.e. subjects treated with beta blockers and cholesterol lowering drugs felt worse compared to subjects on placebo).
(d) Subjects treated with beta blockers and cholesterol lowering drugs found it took between 12% to 40% more perceived cardiorespiratory effort to complete the walks compared to subjects on placebo.
(e) Subjects treated with beta blockers and cholesterol lowering drugs found it took between 22% to 40% more perceived leg effort to complete the walks compared to subjects on placebo.
(f) Subjects treated with beta blockers and cholesterol lowering drugs suffered 22% to 45% more perceived leg pain compared to subjects on placebo.

In healthy volunteers, this study revealed that combinations of beta blockers and cholesterol lowering drugs were associated with increased fatigue during moderate intensity exercise.